Plasma IL-35 in Mature T-Cell Neoplasms: An Exploratory Single-Centre Study
References
- HUANG J, CHAN SC, LOK V, ZHANG L, LUCERO-PRISNO DE 3RD, XU W, et al. Global burden, risk factors, and trends of non-Hodgkin lymphoma: A worldwide analysis of cancer registries. Cancer Med. 2024;13(5).
- LIU S, LIU W, LI H, YANG L, SONG Y, ZHANG X, et al. Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study. Front Oncol. 2022;12:863269.
- SHEA L, MEHTA-SHAH N. Peripheral T-cell lymphoma: Are all patients high risk? Blood. 2024;144:2604–2612.
- REUNAMO T, KALASHNIKOV I, LAHTELA K, POLLARI M, VIISANEN L, MANNISTO S, et al. A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma. Sci Rep. 2025;15:27077.
- FOLEY NC, MEHTA-SHAH N. Management of Peripheral T-cell Lymphomas and the Role of Transplant. Curr Oncol Rep. 2022;24(11):1489–1499.
- NGU HS, SAVAGE KJ. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas. Haematologica. 2023;108(12):3211–3226.
- KATSUYA H, YAMANAKA T, ISHITSUKA K, UTSUNOMIYA A, SASAKI H, HANADA S, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012;30:1635–1640.
- RAHMAN S, ALVAREZ SOTO A, QUNAJ L, YE K, PRADHAN K, THAKKAR A, et al. Prognostic factors for North American adult T-cell leukemia lymphoma: defining risk groups using a four-point score prognostic system. Blood. 2020;136(Suppl 1):38–39.
- KATSUYA H, SHIMOKAWA M, ISHITSUKA K, KAWAI K, AMANO M, UTSUNOMIYA A, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017;130:39–47.
- VEGA F, AMADOR C, CHADBURN A, HSI ED, SLACK G, MEDEIROS LJ, et al. Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up. Mod Pathol. 2022;35(3):306–318.
- FIORE D, CAPPELLI LV, BROCCOLI A, ZINZANI PL, CHAN WC, INGHIRAMI G. Peripheral T cell lymphomas: from the bench to the clinic. Nat Rev Cancer. 2020;20:323–342.
- BINNEWIES M, ROBERTS EW, KERSTEN K, CHAN V, FEARON DF, MERAD M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–550.
- HANAHAN D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022;12(1):31–46.
- BACHMANN MF, OXENIUS A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8(12):1142–1148.
- TOOMER KH, LUI JB, ALTMAN NH, BAN Y, CHEN X, MALEK TR. Essential and non-overlapping IL-2Rα-dependent processes for thymic development and peripheral homeostasis of regulatory T cells. Nat Commun. 2019;10:1037.
- CARLINI V, NOONAN DM, ABDALALEM E, GOLETTI D, SANSONE C, CALABRONE L, et al. The Multifaceted Nature of IL-10: Regulation, Role in Immunological Homeostasis and Its Relevance to Cancer, COVID-19 and Post-COVID Conditions. Front Immunol. 2023;14:1161067.
- BRUNEAU J, CANIONI D, RENAND A, MARAFIOTI T, PATERSON JC, MARTIN-GARCIA N, et al. Regulatory T-cell depletion in angioimmunoblastic T-cell lymphoma. Am J Pathol. 2010;177(2):570–574.
- TRIPODO C, GRI G, PICCALUGA PP, FROSSI B, GUARNOTTA C, PICONESE S, et al. Mast Cells and Th17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma. Am J Pathol. 2010;177(2):792–802.
- HAM JS, PARK HY, RYU KJ, KO YH, KIM WS, KIM SJ. Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. Oncotarget. 2017;8(44):76231–76240.
- SAWADA L, NAGANO Y, HASEGAWA A, KANAI H, NOGAMI K, ITO S, et al. IL-10-mediated signals act as a switch for lymphoproliferation in human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13(9):e1006597.
- NAKAHATA S, ENRIQUEZ-VERA D, JAHAN MI, SUGATA K, SATOU Y. Understanding the Immunopathology of HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: A Comprehensive Review. Biomolecules. 2023;13(10):1543.
- EL HAJJ H, BAZARBACHI A. Interplay between Innate Immunity and the Viral Oncoproteins Tax and HBZ in the Pathogenesis and Therapeutic Response of HTLV-1-Associated Adult T Cell Leukemia. Front Immunol. 2022;13:957535.
- SU LC. Emerging Role of IL-35 in Inflammatory Autoimmune Diseases. Autoimmun Rev. 2018;17(7):754–759.
- COLLISON LW, WORKMAN CJ, KUO TT, BOYD K, WANG Y, VIGNALI KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–569.
- CHOI J, LEUNG PSC, BOWLUS CL, GERSHWIN ME. IL-35 and autoimmunity: a comprehensive perspective. Clin Rev Allergy Immunol. 2015;49(3):327–332.
- DIXON KO, VAN DER KOOIJ SW, VIGNALI DAA, VAN KOOTEN C. Human tolerogenic dendritic cells produce IL-35 in the absence of other IL-12 family members. Eur J Immunol. 2015;45(6):1736–1747.
- XUE W, YAN D, KAN Q. Interleukin-35 as an Emerging Player in Tumor Microenvironment. J Cancer. 2019;10(9):2074–2082.
- TURNIS ME, SAWANT DV, SZYMCZAK-WORKMAN AL, ANDREWS LP, DELGOFFE GM, YANO H, et al. Interleukin-35 Limits Anti-Tumor Immunity. Immunity. 2016;44(2):316–329.
- ERZAR E, TZANKOV A, OCVIRK J, GRČAR KUZMANOV B, BOLTEŽAR L, KLOBOVES PREVODNIK V, et al. FoxP3+ regulatory T-cell quantities in nodal T-follicular helper cell lymphomas and peripheral T-cell lymphomas not otherwise specified and their impact on overall survival. Cancers (Basel). 2024;16(23):4011.
- PENG F, QIN Y, MU S, LI J, AI L, HU Y. Prognostic role of regulatory T cells in lymphoma: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2020;146(12):3123–3135.
- GESSAIN A, CASSAR O. Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol. 2012;3:388.
- IORDAN I, VLĂDĂREANU AM, MAMBET C, ONISÂI M, CÎȘLEANU D, BUMBEA H. Clinical features and survival outcome in aggressive-type adult T-cell leukemia/lymphoma patients: real-life experience of a single center from an HTLV-1 endemic country. Medicina (Kaunas). 2024;60(6):872.
- SULLIVAN JA, TOMITA Y, JANKOWSKA-GAN E, LEMA DA, ARVEDSON MP, NAIR A, et al. Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance. Cell Rep. 2020;30(4):1039–1051.e5.
- SULLIVAN JA, ALADRA DP, OLSON BM, MCNEEL DG, BURLINGHAM WJ. Infectious tolerance as seen with 2020 vision: the role of IL-35 and extracellular vesicles. Front Immunol. 2020;11:1867.
- LIU J, DONG N, LI N, ZHAO H, LI Y, MAO H, et al. IL-35 enhances angiogenic effects of small extracellular vesicles in breast cancer. FEBS J. 2022;289(12):3489–3504.
- JONES LL, CHATURVEDI V, UYTTENHOVE C, VAN SNICK J, VIGNALI DAA. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family. Mol Immunol. 2012;51(2):234–244.
DOI: https://doi.org/10.2478/rjim-2026-0026 | Journal eISSN: 2501-062X (formerly 1220-4749) | Journal ISSN: 1220-4749
Language: English, Romanian
Submitted on: Oct 25, 2026
Published on: Oct 30, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Alexandru Bardas, Mihaela Uta, Ana Manuela Crisan, Valeria Tica, Miruna Elena Tirnovan, Alina Buse, Camelia Ghita, Sandu Horia Mihail, Camelia Dobrea, Daniel Coriu, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.